Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.61 |
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | FLT3 | P36888 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19879204 | 0.86 | P2RX1 (0.56) | NPC1RAB9AMEN1KMT2AFLT3 | |
| SCHEMBL11105052 | 0.85 | FLT3 (0.78) | NPC1RAB9AMEN1KMT2AFLT3 | |
| SCHEMBL13055933 | 0.81 | P2RX1 (0.55) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9416804 | 0.79 | MAPK14 (0.55) | NPC1RAB9AMEN1KMT2AFLT3 | |
| SCHEMBL4903102 | 0.78 | RAF1 (0.48) | NPC1RAB9AMEN1KMT2AFLT3 | |
| SCHEMBL9416824 | 0.78 | RAB9A (0.57) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30788250 | 0.76 | RAB9A (1.00) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9416888 | 0.76 | EGFR (0.47) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8765373 | 0.76 | CNR1 (0.48) | NPC1RAB9AMEN1KMT2AFLT3 | |
| SCHEMBL13055931 | 0.75 | RAB9A (0.53) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132551-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PFIZER INC | 2008-06-05 | — | — | US | disclosed |
| EP-1611128-A2 | POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR | Pharmacia & Upjohn Company LLC (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004085433-A2 | POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-07 | — | — | WO | disclosed |
| EP-0220947-B1 | Polyfluoroalkylisoxazolylamines, their preparation and use | SHIONOGI & CO (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-4797492-A | INTERMEDIATES FOR BACTERICIDES; HERBICIDES OR FUNGICIDES | SHIONOGI & CO., LTD. (JP) | 1989-01-10 | — | — | US | disclosed |
| EP-0220947-A2 | Polyfluoroalkylisoxazolylamines, their preparation and use | SHIONOGI & CO., LTD. (JP) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132551-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | CHRNA1, CHRNA7, CHRNA5 | NPC1 2122/4885RAB9A 888/4885MEN1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.